TMS for Cognitive Decline
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking medications that can cause seizures, like clozapine or high doses of bupropion.
What data supports the effectiveness of the treatment Active rTMS for cognitive decline?
Research shows that repetitive transcranial magnetic stimulation (rTMS) can improve cognitive function in older adults with cognitive impairment and Alzheimer's disease. In one study, patients receiving real rTMS showed a trend toward improved cognitive scores, suggesting potential benefits for cognitive decline.12345
Is repetitive transcranial magnetic stimulation (rTMS) safe for humans?
Repetitive transcranial magnetic stimulation (rTMS) has been used safely in both healthy individuals and those with various brain conditions since the 1990s. While it can cause some adverse events like seizures, safety guidelines have been established and updated over the years to minimize risks. Generally, rTMS is considered safe when used according to these guidelines.678910
How does the treatment rTMS differ from other treatments for cognitive decline?
Repetitive transcranial magnetic stimulation (rTMS) is unique because it uses magnetic fields to stimulate specific areas of the brain, which can improve cognitive functions like memory and attention. Unlike medications, rTMS is non-invasive and does not involve taking drugs, making it a novel option for those with cognitive decline.134511
What is the purpose of this trial?
In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical Alzheimer's disease.This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls cognition. Changes resulting from this stimulation will be measured with behavioral tests, as well as by taking brain images with Magnetic Resonance Imaging (MRI).Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.
Eligibility Criteria
This trial is for older adults who are either cognitively healthy or have mild cognitive impairment, which can be an early sign of Alzheimer's. Participants should not have any serious medical conditions and must be able to attend multiple study visits over several weeks.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline and rTMS Treatment
Participants undergo a baseline visit followed by 10 days of daily rTMS study visits and an evaluation visit
Break
Participants take a 2-week break from the study
Second Baseline and rTMS Treatment
Participants return for another baseline visit, 10 days of rTMS, and a final evaluation visit
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Active rTMS
- Sham rTMS
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor